Form: 8-K

Current report filing

November 13, 2023

Documents

false 0001335105 0001335105 2023-11-13 2023-11-13 0001335105 us-gaap:CommonStockMember 2023-11-13 2023-11-13 0001335105 LIXT:WarrantToPurchaseCommonStockMember 2023-11-13 2023-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 13, 2023

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

delaware   001-39717   20-2903526

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

680 East Colorado Blvd. Suite 180

Pasadena, California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   LIXT   The Nasdaq Stock Market LLC
Warrant to Purchase Common Stock   LIXTW   The Nasdaq Stock Market LLC

 

 

 

 

 

 

Item 8.01 Other Events

 

On November 13, 2023, the Company issued a press release with respect to an update on positioning the Company’s lead compound, LB-100, to enhance chemotherapy and immunology.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

We are filing as part of this Report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 13, 2023 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
     
  By: /s/ BASTIAAN VAN DER BAAN
   

Bastiaan van der Baan,

President and Chief Executive Officer

 

-3-

 

 

INDEX TO EXHIBITS

 

Exhibit No.   Description
     
99.1   Press Release with respect to an update on positioning the Company’s lead compound, LB-100, to enhance chemotherapy and immunotherapy
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

-4-